Agios Pharmaceuticals Misses Q3 Earnings and Revenue Estimates
AGIO Stock | USD 29.18 0.92 3.26% |
About 56% of all Agios Pharm's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Agios Pharm suggests that some traders are interested. Agios Pharm's investing sentiment overview a quick insight into current market opportunities from investing in Agios Pharm. Many technical investors use Agios Pharm stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Agios Pharmaceuticals delivered earnings and revenue surprises of -74.84 percent and 4.29, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock
Read at zacks.com
![]() |
Agios Pharm Fundamental Analysis
We analyze Agios Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Agios Pharm is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Agios Pharm Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Agios Pharm stock to make a market-neutral strategy. Peer analysis of Agios Pharm could also be used in its relative valuation, which is a method of valuing Agios Pharm by comparing valuation metrics with similar companies.
Peers
Agios Pharm Related Equities
MRSN | Mersana Therapeutics | 9.68 | ||||
ARVN | Arvinas | 3.67 | ||||
CGEM | Cullinan Oncology | 3.59 | ||||
IDYA | Ideaya Biosciences | 2.95 | ||||
MREO | Mereo BioPharma | 2.75 | ||||
KALV | Kalvista Pharmaceuticals | 2.32 | ||||
COGT | Cogent Biosciences | 2.31 | ||||
BPMC | Blueprint Medicines | 2.21 | ||||
BMRN | Biomarin Pharmaceutical | 1.72 | ||||
DAWN | Day One | 1.46 | ||||
STOK | Stoke Therapeutics | 1.35 | ||||
SNDX | Syndax Pharmaceuticals | 1.12 | ||||
NRIX | Nurix Therapeutics | 1.06 | ||||
BDTX | Black Diamond | 1.04 | ||||
KYMR | Kymera Therapeutics | 0.77 | ||||
CCCC | C4 Therapeutics | 0.73 | ||||
PLRX | Pliant Therapeutics | 0.73 | ||||
RLAY | Relay Therapeutics | 0.72 | ||||
KROS | Keros Therapeutics | 0.29 | ||||
RVMD | Revolution Medicines | 0.25 | ||||
ANAB | AnaptysBio | 0.88 | ||||
MGTX | MeiraGTx Holdings | 0.99 |
Check out Agios Pharm Hype Analysis, Agios Pharm Correlation and Agios Pharm Performance. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.